Nichole Tucker

Bosutinib has a new indication in leukemia as a well as a newly-approved formulation.

In an interview with Targeted Oncology, Rachna T. Shroff, MD, MS, FASCO, discussed new systemic therapies that are available or being developed to treat patients with patients with intrahepatic cholangiocarcinoma.

Activation of the JAK/STAT pathway with ruxolitinib may be a future option for patients with newly diagnosed, high-grade glioma.

In an interview with Targeted Oncology, Penn Medicine’s Qian Wang, MD, MPH, gives an in-depth overview of the molecular targets in the small cell lung cancer field.

In an interview with Targeted Oncology™, Michelle M. Issac, MD, discussed the goals of both palliative care and oncology care professionals as they support patients with cancer.

In an interview with Targeted Oncology, Muhammad Siddiqui, MD, explained the role that palliative medicine plays in a cancer treatment plan and how oncologists and palliative care physicians can work together in patients’ best interests.

MJH Life Sciences ™ - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Treatment with luspatercept led to decreases in red blood cell transfusion (RBCT) burden compared to epoetin alfa in patients with erythropoiesis-stimulating agent (ESA)-naive lower-risk myelodysplastic syndromes (LR-MDS).1

In low-blast, high-risk myeloid diseases, including myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), vibecotamab appeared well-tolerated and safe with no dose reductions required and no patients discontinuing treatment due to adverse events (AEs).

The FDA has granted approval to concizumab-mtci injection (Alhemo) for the prevention or reduction in frequency of bleeding episodes in patients aged 12 years and older with hemophilia A or B with inhibitors, according to an announcement issued by Novo Nordisk.1